1. Home
  2. SILO vs NDRA Comparison

SILO vs NDRA Comparison

Compare SILO & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.29

Market Cap

4.5M

ML Signal

HOLD

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

HOLD

Current Price

$3.51

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILO
NDRA
Founded
2010
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
5.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SILO
NDRA
Price
$0.29
$3.51
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$30.00
AVG Volume (30 Days)
103.7K
27.5K
Earning Date
03-30-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$72,102.00
N/A
Revenue This Year
$1.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$2.90
52 Week High
$1.57
$11.96

Technical Indicators

Market Signals
Indicator
SILO
NDRA
Relative Strength Index (RSI) 35.36 34.60
Support Level $0.29 $3.48
Resistance Level $0.33 $3.78
Average True Range (ATR) 0.03 0.34
MACD -0.00 -0.02
Stochastic Oscillator 19.14 18.99

Price Performance

Historical Comparison
SILO
NDRA

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Share on Social Networks: